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Abstract
Background: Polycistronic retroviral vectors that contain several therapeutic genes linked via
internal ribosome entry sites (IRES), provide new and effective tools for the co-expression of
exogenous cDNAs in clinical gene therapy protocols. For example, tricistronic retroviral vectors
could be used to genetically modify antigen presenting cells, enabling them to express different co-
stimulatory molecules known to enhance tumor cell immunogenicity.
Results: We have constructed and compared different retroviral vectors containing two co-
stimulatory molecules (CD70, CD80) and selectable marker genes linked to different IRES
sequences (IRES from EMCV, c-myc, FGF-2 and HTLV-1). The tricistronic recombinant
amphotropic viruses containing the IRES from EMCV, FGF-2 or HTLV-1 were equally efficient in
inducing the expression of an exogenous gene in the transduced murine or human cells, without
displaying any cell type specificity. The simultaneous presence of several IRESes on the same
mRNA, however, can induce the differential expression of the various cistrons. Here we show that
the IRESes of HTLV-1 and EMCV interfere with the translation induced by other IRESes in mouse
melanoma cells. The IRES from FGF-2 did however induce the expression of exogenous cDNA in
human melanoma cells without any positive or negative regulation from the other IRESs present
within the vectors. Tumor cells that were genetically modified with the tricistronic retroviral
vectors, were able to induce an in vivo anti-tumor immune response in murine models.
Conclusion: Translation of the exogenous gene is directed by the IRES and its high level of
expression not only depends on the type of cell that is transduced but also on the presence of other
genetic elements within the vector.
Background
Gene therapy protocols would strongly benefit from the
development of a one step technique that would allow
cells to be genetically modified through the introduction
of several therapeutic genes. In order to induce the trans-
lation and expression of exogenous cDNAs, carried by a
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single vector, researchers have cloned internal ribosomal
entry sites (IRES) upstream from these exogenous cDNAs.
This approach should lead to the translation of three cis-
trons from an unique mRNA and therefore to the conse-
quent expression of the three encoded proteins [1-6].
In most cases, the IRES from EMCV is cloned into polycis-
tronic vectors as it induces high levels of DNA translation
[3,7,8]. The capacity of other IRESes to induce high levels
of exogenous cDNA expression in different cell types has
been compared to the capacity of the EMCV IRES [2-4,9-
11]. However, in most cases, these comparisons were car-
ried out after different IRESes had been inserted into a sin-
gle, characterized, dicistronic (one IRES) or tricistronic
(two IRESes) mRNA and after the in vitro vector transla-
tion efficiency had been established [9-14]. These studies
are useful in choosing the IRES that will drive the in vivo
expression of heterologous proteins, they do, however,
give little information as to the potential in vivo interac-
tions that occur between different IRESs cloned into the
same MuLV-based retroviral vector.
We cloned tricistronic vectors encoding three different
cDNAs. This involved using at least two IRESes to translate
the second and third cistrons. Using the same IRES twice
in a single vector could, however, induce recombination
events and the loss of the second IRES and cistron. In the
same way, using the same cistron twice could lead to a
competition between the two IRESs for the binding to cell
type specific translation factors. For these reasons, we
chose to clone and compare the efficiency of different
IRESes cloned into the same vector. We chose the IRES of
EMCV (IRESEMCV), the IRES of the c-myc proto-oncogene
(IRESC-MYC), the IRES of FGF-2 (IRESFGF-2) and the IRES of
the HTLV-1 lentivirus (IRESHTLV-1) [1,8,15-22]. The vec-
tors were constructed so that the third cistron was trans-
lated from the IRESEMCV  and the second cistron was
translated from the IRESEMCV, IRESC-MYC,, IRESFGF-2  or
IRESHTLV-1.
Recently, it has been shown that retroviral vectors derived
from MuLV contain an additional IRES on the 5' gag
sequence [20,23]. The vectors described here contained
three IRESes: the IRES from MuLV located between the
LTR and the Psi sequence controlling the translation of
the first cistron, the IRES from a different origin and the
IRES from EMCV respectively controlling the translation
of the second and third cistrons (Figure 1A and 1B). The
exogenous genes cloned into the tricistronic vectors were
chosen for their potential use in clinical trials. They code
for co-stimulatory molecules known to enhance tumor
cell immunogenicity: CD80, a member of the B7 family
and CD70, a member of the TNF family [7,24-26]. These
molecules act in synergy to enhance the induction of Ag-
mediated anti-tumor immunity when co-expressed with
tumor antigens [7,24,25,27]. We generated retroviral vec-
tors that encoded the two co-stimulatory molecules CD70
and CD80, and a selection gene. We compared the efficacy
of these vectors in their capacity to genetically modify var-
ious human and murine cells, and also observed how they
affected the selection and culture of these cells following
transduction. We then compared the expression of the
three exogenous genes within the genetically modified
cells. Murine melanoma cells were then tested in two dif-
ferent murine tumor models for their ability to induce an
in vivo anti-tumor immune response, regardless of the per-
centage of co-stimulatory molecules expressed by the
transduced cells.
Results
Construction of tricistronic retroviral vectors expressing 
CD70 and CD80
We constructed tricistronic vectors that would induce the
expression of three cDNAs (CD70, CD80 and a selection
gene) from one promoter (LTR viral promoter) (Figure 1).
The constructions are described in the Methods. Expression
of the first open reading frame (cDNA encoding a co-stim-
ulatory molecule) occurs from one IRES (MuLV) located
at the 5' extremity of the mRNA. The second and third
open reading frames are translated from two identical or
two different IRESes. TFGEMCVNEO or TFGEMCVZEO were
constructed so that the translation of the selection gene
and the second co-stimulatory molecule could be induced
from two identical IRESEMCV (Figure 1A). TFGHTLV-1, TFGC-
MYC and TFGFGF-2 were constructed to allow the expression
of the selection gene from IRESHTLV-1, IRESC-MYC or IRES-
FGF-2 while the translation of the third open reading frame
was under the control of IRESEMCV (Figure 1B).
Efficiency of the different IRESes in inducing the 
expression of the selection gene (NEO or ZEO) in different 
cell types
We generated retroviral vectors using the different plas-
mids described in Figure 1 and transfected ψCRIP cells or
triple-transfected the 293T packaging cell line. We
obtained viable G418 or zeocin-resistant ψCRIP cells after
transfection with TFGEMCVNEO, TFGEMCVZEO, TFGHTLV-
1ZEO, TFGHTLV-1NEO, TFGFGF-2ZEO or TFGFGF-2NEO but
none after transfection with TFGcMYCZEO or TFGcMYC-
NEO. We tested the supernatants from ψCRIP or 293T
transfected cell suspensions for the presence of replication
competent retroviruses (RCR) through the dosage of
reverse transcriptase activity. The supernatants from all
the transfected packaging cells were free of reverse tran-
scriptase activity. The titers of the different retroviruses
produced different results, depending on the experiments,
varying from 104 to 106 particles/ml. We used 105 particles
of each type of retrovirus that was produced (TFGFGF-
2ZEO, TFGHTLV-1ZEO or TFGEMCVZEO) or the 48 hour
supernatants from transiently transfected TFGcMYCZEOBMC Biotechnology 2004, 4:16 http://www.biomedcentral.com/1472-6750/4/16
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Structure of retroviral constructs Figure 1
Structure of retroviral constructs. TFG vectors are MFG-based retroviral plasmids into which the hCD70 cDNA and 
hCD80 cDNAs have been cloned, with either a neoR or a zeoR selectable marker gene. The three genes are co-translated 
from a tricistronic mRNA which was transcribed from the 5' long terminal repeat. The translation of the first cDNA (CD70 or 
CD80) depends on the 5' long terminal repeat-gag IRES, while the translation of the selectable marker and the second cDNA 
(CD70 or CD80) are dependent on two IRESes from different origins.
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ψCRIP or 293T cells to transduce different types of mam-
malian cells. The murine cells used were either NIH-3T3
fibroblasts or B16.F10 melanoma cells. To establish a
human model, we cultured melanoma cells from biopsies
as described in the Methods. During the course of this
study we obtained 23 melanoma biopsies. Fifteen cell cul-
tures were obtained from these biopsies which represents
a yield of 65 %. The quality and characteristics of the
melanoma cells were determined by immunohistochem-
istry, on cytospin cells, using anti-cytokeratin (KL-1) (neg-
ative control), anti-S100 protein, anti-melanA/MART1
and anti-HMB-45/gp100 antibody staining as described
in the Methods. The 15 human cell cultures obtained all
stemmed from melanoma cells (data not shown).
The transduced cells were selected for their resistance to
G418 or zeocin. Fifteen days after the transduction with
each retroviral vector, we selected G418 or zeocin-resist-
ant cells. Apart from the TFGCMYCZEO transduced cells, we
obtained roughly the same number of zeocin or G418
resistant clones with the different retroviral constructs.
Both murine and human cells could be successfully genet-
ically modified using the engineered trigenic retroviral
vectors. No vector was statistically more efficient in
obtaining a higher yield of resistant clones. However, the
TFGEMCVZEO, TFGFGF-2ZEO and TFGHTLV-1ZEO cells were
long lasting, viable and could be expanded, whereas nei-
ther murine nor human TFGcMYCZEO transfected cells dis-
played long-term viability.
The selected genetically modified cells expressed co-
stimulatory molecule mRNAs
Cells were stably transduced with MFG derived vectors
encoding CD70, CD80 and an antibiotic resistance gene.
After selection with the appropriate antibiotics (G418 or
Zeocin), the stably transduced cells were analyzed for the
expression of the different mRNAs, by RT-PCR using spe-
cific primers. The aim of the RT-PCR analysis was to show,
through the expression of the full length RNA, that suc-
cessful transcription of the construct had been achieved.
We were uncertain whether the transcription of the
ectopic DNA was complete. RT-PCR analysis was per-
formed using cells that were resistant to Zeocin. We are
convinced that the mRNA transcribed from the ectopic
DNA contains the IRES zeocin cassettes. As we can noticed
in figure 2A, the primers used for PCR analysis n°4 and 5
overlapped. They hybridized with the sequence corre-
sponding to the ZEO gene. Our hypothesis is that if we
can amplify the two segments of the construction (CD70-
IRES-ZEO and ZEO-IRES-CD80 or CD80-IRES-ZEO and
ZEO-IRES-CD70) at the same time from the ectopic RNA,
then the full length RNA had been transcribed. We have
already performed other RT-PCR analyses using this the
long ranger taq polymerase from Applied (France). We
have been able to amplify full length RNA from all con-
structs (data not shown). Taken together our data strongly
suggests that the full length RNA was transcribed from all
the viral constructs.
These RT-PCR results suggest that there was no downreg-
ulation of CD70 or CD80 expression at the transcriptional
and post-transcriptional levels.
The selected genetically modified cells expressed the co-
stimulatory molecules at different levels
The cell populations were tested for co-stimulatory mole-
cule expression by flow cytometry using Abs that were
directed against CD70 and CD80. Within a given popula-
tion, a large percentage of cells expressed the two co-stim-
ulatory molecules in a stable manner and at high levels.
Figure 3F shows the results of the flow cytometric analysis
of human melanoma cells transduced with TFGFGF-2ZEO.
Figure 3 is representative of the cytometric analyses car-
ried out on the murine B16.F10 melanoma cells trans-
duced with 48 hr supernatants of 293T cells transfected
with the 4 different types of retroviral vectors. A high per-
centage of B16.F10 cells transduced with TFGFGF2ZEO or
TFGHTLV-1ZEO retroviral vectors (Fig. 3D and 3E respec-
tively) expressed both co-stimulatory molecules.
The percentage of B16.F10 cells, transduced with TFGEM-
CVZEO or TFGc-MYCZEO, expressing only CD80 was higher
than the percentage of cells expressing only CD70 or both
molecules (Fig. 3B and 3C respectively).
The level of expression of the two molecules differed
depending on the vectors used and the cell types that were
transduced, as shown in Table 1 - see additional file 1.
In theory, selected clones expressed both molecules. In
fact, in any selected clone, we found cells that expressed
only one of the molecules (CD70 or CD80) and cells that
expressed the two molecules.
Murine cells
In murine cells (either fibroblasts or melanoma cells), a
high percentage of cells only expressed CD70. This was
not due to the expression of the CD70 molecule, in itself.
Indeed, when we used constructs with CD80 as the first
cistron, we obtained a high percentage of cells that only
expressed CD80. This percentage could be attributed to a
negative regulation of the translation of the third cistron.
Even after the selection of transfected cells, we obtained
cells which did not express detectable levels of co-stimula-
tory molecules. Indeed, in TFGHTLV-1ZEO, TFGFGF-2ZEO or
TFGEMCVZEO transduced murine NIH-3T3 cells, we
respectively found 35%, 31% or 44% of cells that
expressed undetectable levels of CD70 or CD80.BMC Biotechnology 2004, 4:16 http://www.biomedcentral.com/1472-6750/4/16
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Expression levels were assessed regardless of the resistance
gene that was used (NEO or ZEO).
We tested the expression of the two co-stimulatory mole-
cules immediately after transduction or after selection. No
correlation could be established between the time of anal-
ysis and the percentage of cells expressing both molecules.
One clone could be composed of a majority of cells (60%)
expressing both molecules at day 5 post selection, only
have a small percentage of these cells at day 15 and up to
95 % on day 25. Indeed, even within a selected popula-
tion of cells, the percentage expressing both co-stimula-
tory molecules could vary from 5 up to 95 % of the total
cell number.
After transduction with a single vector, 20 clones were
selected. Within the same clone, some cells expressed only
one co-stimulatory molecule whereas others expressed
both molecules. These observations are reflected by the
high SD of the percentage of cells expressing co-stimula-
tory molecules (Table 1 - see additional file 1).
None of the vectors used were found to be adequate for
the transfection of murine cells.
RT-PCR analysis of mRNA transcribed from the tricistronic vectors in stably transduced melanoma cells Figure 2
RT-PCR analysis of mRNA transcribed from the tricistronic vectors in stably transduced melanoma cells. 2A : 
Localization of the different primers. Figure 2B: cDNA obtained after reverse transcription was amplified using primers 1 and 5 
(lanes 1 to 4) or primers 4 and 10 (lanes 5 to 8) as described in Methods. Lanes 1 and 5: RT-PCR performed on mRNA isolated 
from TFGFGF-2ZEO transduced cells (1819 and 1640 bp amplified respectively). Lanes 2 and 6: RT-PCR performed on mRNA 
isolated from TFGEMCVZEO transduced cells (1819 and 1640 bp amplified respectively). Lanes 3 and 7: RT-PCR performed on 
mRNA isolated from TFGHTLV-1ZEO transduced cells (1510 and 1640 bp amplified respectively). Lanes 4 and 8: RT-PCR per-
formed on mRNA isolated from mock retroviral vector transduced cells (negative controls).
MFG-BASED RETROVIRAL VECTORS – PRIMERS LOCALIZATION
IRES de MuLV  IRES
CMYC => TFG-cMYC 
IRES
EMCV => TFG-EMCV 
IRES
FGF-2 => TFG-FGF-2 
IRES
HTLV-1 => TFG-HTLV-1
LTR CD70  IRES  ZEO  IRES
EMCV CD80  LTR
Trigen 1  Trigen 4 
Trigen 5  Trigen 10 
Psi
Lambda 
Hind III 1          2          3         4                5          6          7        8
1 and 5
primers
4 and 10
primers 
RT-PCR AnalysisBMC Biotechnology 2004, 4:16 http://www.biomedcentral.com/1472-6750/4/16
Page 6 of 12
(page number not for citation purposes)
Human cells
For human cells, we chose to use a pool of transduced
cells, rather than clones, to stay as close as possible to the
reality of human clinical protocols. When we used
TFGHTLV-1ZEO (CD80 first) or TFGHTLV-1ZEO2 (CD70
first) we obtained cells that expressed only the first cis-
tron. We obtained a better yield of cells expressing the two
co-stimulatory molecules when using the TFGFGF-2ZEO
construct (70% of cells expressing the two molecules in a
stable manner). Again, even within a selected population
Example of co-stimulatory molecule expression by melanoma cells after transduction with TFG tricistronic vector: Immunos- taining with hCD80 – (x-axis) and hCD70 – (y-axis) Figure 3
Example of co-stimulatory molecule expression by melanoma cells after transduction with TFG tricistronic 
vector: Immunostaining with hCD80 –(x-axis) and hCD70 – (y-axis) 3A: non transduced melanoma cells were cul-
tured. Ccells (3 × 105) was stained for surface expression of CD70 and CD80 using specific antibodies as described in the 
Methods. 3B-3E: Murine B16.F10 melanoma cells were transduced with the four TFG retroviral vectors. Forty eight hours 
after transduction, pools of cells (3 × 105) were stained for surface expression of CD70 and CD80 using specific antibodies as 
described in the Methods. 2B: TFGEMCVZEO transduced cells, 2C: TFGc-MYCZEO transduced cells, 2D: TFGFGF-2ZEO trans-
duced cells, 2E: TFGHTLV-1ZEO transduced cells.3F: Human melanoma cells were transduced with the TFGFGF-2ZEO. A 
selected pool of cells (3 × 105) was stained for surface expression of CD70 and CD80 using specific antibodies as described in 
the Methods. The samples were subjected to two-color analysis by flow cytometry. Data are shown as immunofluorescence 
profiles with arbitrary fluorescence units (log) of FITC on the x-axis and immunofluorescence profiles with arbitrary fluores-
cence units (log) of PE on the y-axis. To evaluate the percentage of co-stimulatory molecules expressed by transfected cells, 
the marker was set to allow < 5% positive cells in the non-transduced cells.
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of cells, the percentage of cells expressing both co-stimu-
latory molecules could vary considerably (from 45 to 95
% of total cell number).
In human melanoma cells, the use of tricistronic vectors
in which IRESFGF-2 induced the translation of the second
cistron, and IRESEMCV the translation of the third cistron,
led to a high percentage of cells expressing the three
cistrons.
Expression of the tricistronic transgene slows the tumor 
growth rate after s.c. injection of B16.F10 in an established 
model
Among selected cells, the percentage expressing both co-
stimulatory molecules varied. We have previously shown
that melanoma cells expressing high levels of CD70 alone
or in combination with CD80 induced in vitro splenocyte
proliferation [7]. Using a pool of selected cells that were
genetically modified by TFGHTLV-1ZEO (52 % CD70, 21 %
both CD70 and CD80), TFGFGF-2ZEO (5 % CD70, 33 %
both CD70 and CD80), TFGEMCVZEO (27 % CD70, 16 %
both CD70 and CD80) or double-transfected with DFG
CD70 and DFG CD80 (>65 % both CD70 and CD80), we
showed that different percentages of cells expressing both
co-stimulatory molecules (even as little as 20 %) could
induce a proliferative response in splenocytes. A substan-
tial increase in spleen cell proliferation was observed
when the two molecules were expressed following genetic
modification with all the viral vectors. This increase was
similar to that induced by the use of double transfected
cells (data not shown).
To determine whether the local expression of CD70 and
CD80 could affect tumor establishment, we sub-cutane-
ously injected 105 cells, from each type of tumor, into the
flanks of C57BL/6 mice (Figure 4A). These cells had previ-
ously been used in splenocyte proliferation experiments.
Subcutaneous injection of B16.F10 cells into B6 syngeneic
immunocompetent mice led to the development of
tumors. However, there was a delay in the appearance of
tumors derived from transduced or double-transfected
cells compared with tumors induced by the inoculation of
parental or mock-transfected cells (control B16.F10 cells
transfected with a retroviral vector encoding the zeocin-
resistance gene). Although, all mice had palpable tumors
before day 10, the growth rate was significantly slower for
TFGFGF-2ZEO or TFGHTLV-1ZEO transduced cell tumors
compared to parental cell tumors (p < 0,01) and double
transfected cell tumors (p < 0.001) on day 20 (Figure 4A).
This decrease in tumor growth was less pronounced in
tumors derived from cells modified by tricistronic vectors
than in tumors derived from cells modified by two inde-
pendent vectors. This could be due to the level of expres-
sion of the co-stimulatory molecules on the cell surface.
We have previously shown that co-expression of the two
co-stimulatory molecules is necessary to induce an in vivo
immune response. Here we show that, for the B16.F10
melanoma cell model, we had to inject as many as 6 × 104
cells (60 % of the injected cells) expressing both co-stim-
ulatory molecules to observe an immune response.
We have previously shown that the anti-tumor effect is
more difficult to obtain in a MHC class I loss variant than
in a MHC class I positive model [7]. To confirm how
important the percentage of cells expressing both co-stim-
ulatory molecules is in inducing an in vivo immune
response, we transduced TS/A adenocarcinoma cells using
the same retroviral vectors, as previously described. We
pooled the zeocin resistant cells and chose two pools. In
the first pool of cells transduced with TFGEMCVZEO, 34 %
only expressed CD70 and 23 % expressed both CD70 and
CD80. In the second pool of cells transduced with TFGFGF-
2ZEO, 73 % only expressed CD70 and 20 % expressed
both CD70 and CD80. These two pools were injected sub-
cutaneously into syngeneic immunocompetent BALB/c
mice. These injections led, in all cases, to the development
of tumors. However, when the cells were double-trans-
fected with two independent vectors and more than 70 %
of cells expressed both co-stimulatory molecules, most of
the palpable tumors spontaneously decreased within 10
days. In contrast, only a delay in the appearance of the
tumors derived from transduced cells could be observed.
This delay was more or less pronounced depending on the
percentage of cells expressing both molecules. There was
no delay in the appearance of tumors derived from the
pool containing 34 % of cells expressing only CD70 and
23 % of cells expressing CD70 and CD80. A delay was
observed in the appearance of tumors derived from the
pool containing 73 % of cells expressing only CD70 and
20 % of cells expressing CD70 and CD80 (figure 4B).
Discussion
In this study, we have constructed and tested different tri-
cistronic retroviral vectors containing IRES elements from
different origins. As IRESes are remarkably efficient when
used in bicistronic vectors, it was particularly interesting
from a biotechnological point of view (for gene therapy
protocols) to design polycistronic vectors that could allow
the expression of several proteins from the same mRNA.
Several authors have reported the construction of different
vectors using the IRESEMCV or the IRESFMDV2A to trigger the
high level expression of an exogenous gene[2-4,10,11,28].
Prats and coll. have described several other IRESes includ-
ing the IRESs from the c-myc proto-oncogene, the IRES
from FGF-2 and the IRES from HTLV-1 [17,18,20,21]. The
first aim of our work was to determine whether one of
these IRESes could induce a higher level of exogenous pro-
tein expression than the IRES from EMCV in different cell
lines. The second aim was to design polycistronic vectors
carrying different IRESes to avoid the risk ofBMC Biotechnology 2004, 4:16 http://www.biomedcentral.com/1472-6750/4/16
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recombination between IRESes. The third aim was to
obtain genetically modified melanoma cells through
transduction with tricistronic retroviral vectors. These
tumor cells would therefore be genetically modified to
express two co-stimulatory molecules, CD70 and CD80,
which are known to induce an anti-tumor response in
syngeneic mice.
As we have generated retroviral vectors derived from the
well known MFG vector (MuLV vector), we already had
one additional IRES upstream from the first ATG codon
(initiation codon of the first exogenous cDNA). This IRES
has been described by Vagner and coll [20]. The first IRES
(MulV) and the third IRES (EMCV) were conserved in all
the vectors. The second IRES responsible for inducing the
translation of the selectable marker, was the IRES from
either EMCV, FGF-2, c-myc or HTLV-1.
The choice of IRES that was used to express the cDNA
encoding the G418 or zeocin-resistance genes was unim-
portant as we obtained resistant cells in all the cell lines
tested: murine tumor cells (B16.F10, TS/A), murine
fibroblasts (NIH3T3), packaging cell line (ψCRIP),
human melanoma and lung adenocarcinoma cells
Effects of CD70 and CD80 co-expression by single transduced tumor cells on tumor growth in an established model Figure 4
Effects of CD70 and CD80 co-expression by single transduced tumor cells on tumor growth in an established 
model. 4A: 105 B16.F10 wt (control cells), or CD70 and CD80 double transduced B16.F10, or CD70 and CD80 single trans-
duced B16.F10 were injected s.c. on day 0 into female C57BL/6 mice. 4B: 105 TS/A wt (control cells), or CD70 and CD80 dou-
ble-transfected TS/A, or CD70 and CD80 single-transfected TS/A were injected s.c. on day 0 in female BALB/c mice. Tumor 
growth was monitored twice a week. The results are expressed as mean size (mm2) of tumors from groups that each contain 
five mice ± SD. The data represent mean +/- SD of a single experiment representative of three.pouet
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(A549). However, when the IRES from the c-myc proto-
oncogene was used, we never obtained long-lasting zeocin
or G418 resistant murine or human cells, whether these
were tumor cells or fibroblasts. So far, most of the cellular
mRNAs that contain IRESes and code for proteins
involved in the control of cell proliferation and differenti-
ation, require stringent regulation like for example the c-
myc  mRNAs [13,15,29,30]. These genes need to be
expressed at very specific stages of the cell cycle and/or in
response to different stimuli [17,19]. This has also been
shown for FGF-2. Indeed the CUG-initiated isoforms of
FGF-2 are translationally activated in response to stress
[21]. Such observations suggest that when the IRESc-myc is
used, translation is strongly downregulated [30].
We obtained long-lasting viable resistant cells when we
used the IRESes from EMCV, FGF-2 or HTLV-1. The
number of clones obtained after transduction or transfec-
tion was roughly the same depending on the experiments
and the cell lines tested. This indicated that only a few (if
any) recombination events occurred when we used the
same IRES (EMCV) twice in the same retroviral vector.
The first and third IRESes are responsible for inducing the
translation of the two co-stimulatory molecules. These
IRESes competed to induce the expression of the two
exogenous cDNAs. Indeed within the same population of
selected cells, whatever the retroviral vector used, we were
able to obtain cells that only expressed the first exon, or
only the third exon or both exons. The percentage of cells
that expressed both co-stimulatory molecules varied with
the cell passage and from one selected clone to another.
This is true regardless of the cell line tested: murine tumor
cells (B16.F10, TS/A), murine fibroblasts (NIH3T3),
murine packaging cell line (ψCRIP), human melanoma
cells and human lung adenocarcinoma cells (A549).
There is a difference in the IRES-dependent mechanism
that occurs in cellular and viral internal initiation. Cur-
rently, two cellular trans-acting factors, the La antigen and
PTB have been found to bind to picornavirus IRES ele-
ments and to be essential for their internal initiation of
translation [29,31,32]. However, these proteins do not
specifically bind to eukaryotic cellular mRNAs with the
same efficiency. IRES function must require either differ-
ent amounts of translation initiation factors or, more
likely, additional proteins similar to those required for the
cap-dependent initiation of protein synthesis [29,33].
Borman and coll. have recently shown that the recogni-
tion of different IRES elements varies within different tis-
sue culture cell lines [9,12]. The activity of a particular
IRES within a cell may be dependent on the relative level
of stimulatory and inhibitory molecules [34]. It is possi-
ble that different trans-acting factors that are dependent
on a specific IRES may be required. It could be that the
MuLV IRES (first exon) binds those trans-acting factors
with a higher affinity than the IRES from EMCV (third
exon). Anthony and Merrick suggested that translation
factors, that have a higher affinity for the cap structure
than for the IRES element, could be sequestered at the
m7GpppN cap structure and would therefore be unavail-
able for the internal initiation of translation at saturating
concentrations of capped bicistronic RNA [1,35]. This
would lead to an increased translation of the first cistron
and a decreased translation of the second and third cis-
trons that are thought to be dependent on internal initia-
tion of translation. In our case, we have an IRES (IRES
MulV) on the 5' end of the mRNA. This IRES induces the
translation of the first co-stimulatory molecule. However,
while the IRES from EMCV or HTLV-1 could interact with
other IRESes present within the retroviral construct (the
IRES from gag or the IRES from EMCV), we found that the
IRES from FGF-2 induced the expression of exogenous
cDNA in human melanoma cells without any positive or
negative regulation from the other IRESes.
We have previously shown that two co-stimulatory mole-
cules (CD70 and CD80), expressed on the surface of
tumor cells could induce an anti-tumor immune response
when the cells were injected into a syngeneic animal
[7,27]. In tumor cells that were genetically modified by
the tricistronic retroviral vector, we attempted to induce
an in vivo anti-tumor response in murine models. We first
showed that B16.F10 cells that were genetically modified
by the tricistronic vectors, could induce in vitro prolifera-
tion of spleen cells. These B16.F10 cells were then injected
into syngeneic animals and tumor growth was monitored.
We observed that in this murine model (C57BL/6) or in
the BALB/c murine model (breast adenocarcinoma TS/A
cells), co-expression of the two co-stimulatory molecules
by at least 50 % of cells was necessary to induce an anti-
tumor response. CD70 expression, alone or in association
with a low level of CD80 expression, was not sufficient to
induce anti-tumor immunity. These findings show that at
least 50 % of the genetically modified cells must express
the CD70 and CD80 co-stimulatory molecules before
starting an immunotherapy protocol. Establishing
cultures of human melanoma cells derived from biopsies
was very difficult, we obtained a low yield of 63 %. We
could infect human melanoma cells with the tricistronic
retroviral vector with an efficiency of 50 %. However,
within the 50 % of cells that were genetically modified we
could only obtain a high percentage of cells expressing
both co-stimulatory molecules when we used the tricis-
tronic recombinant amphotropic viruses obtained with
the IRES FGF-2.
Conclusion
The ability of retroviral vectors carrying IRESes to deliver
genes, in vitro and in vivo, to a variety of dividing cell types
has been applied to research and gene therapy for the pastBMC Biotechnology 2004, 4:16 http://www.biomedcentral.com/1472-6750/4/16
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10 years. Our work shows that it is difficult to chose which
IRES must be inserted into a polycistronic gene therapy
vector, when the aim is to ensure a high level of transla-
tion of the exogenous gene. This level of expression will
depend on the type of cell that is transduced but also on
the presence of other genetic elements within the vector.
Methods
Cell lines
The murine melanoma B16.F10 cell line and the mouse
mammary adenocarcinoma TS/A cell line, previously
described, were cultured in RPMI 1640 supplemented
with 2 mM glutamine and 10% fetal calf serum (FCS)
(GIBCO-BRL, Cergy-pontoise, France). NIH-3T3 cells and
the cysteine-rich intestinal protein (ψCRIP) and 293T
packaging cell lines, were purchased from the American
Type Culture Collection (Rockville, Md, USA). These three
cell lines were cultured in Dulbecco's modified Eagle's
medium supplemented with 10 % FCS [27]. All cell lines
were periodically tested for mycoplasma infection using a
DNA hybridization probe (Stratagene, La jolla, CA, USA).
Primary culture of human melanoma cells
Melanoma tumor biopsies were dissected into small
explants and then enzymatically digested with colla-
genase (5 mg/ml) and hyaluronidase (3 mg/ml) (SIGMA,
Saint Quentin Fallavier, France) for 1 hour at 37°C under
agitation. The cells were then centrifuged (5 minutes at
1200 rpm) and transferred to a culture flask and left to
proliferate for 10 days. These cells were cultured in RPMI
1640 supplemented with 2 mM glutamine, 10% FCS,
non-essential amino acids and vitamins (SIGMA, France).
During the first 4 days after the first passage, cells were cul-
tured with 0.1 mg/ml of G418 (GIBCO-BRL, Cergy-pon-
toise, France) to remove fibroblasts as described by
Mouriaux and coll[36]. The quality and characteristics of
the melanoma cells were studied by immunohistochemis-
try using anti-cytokeratin (KL-1), anti-S100, anti-HMB45/
gp100 and anti-melanA/MART1 (clone A103) antibodies
(all from DAKO SA, Trappes, France).
Retroviral constructs
The pMDgag/pol and pBA-GALV plasmids were obtained
from the Genethon (Evry, France). The tricistronic vectors
are MFG-based retroviral vectors. These vectors were
derived from the DFG-human-CD80 (hCD80) and DFG-
human-CD70 (hCD70) vectors that have previously been
described [7,27]. The first cistron (cDNA encoding
hCD70 or hCD80) was cloned between the Nco1 and
BamH1sites of the MFG vector. The AUG of this molecule
corresponds to the AUG of the env gene of the MFG vector.
Construction of TGFEMCVZEO or NEO
In these vectors, the translation of the genes encoding the
two co-stimulatory molecules and the cDNA encoding the
G418 or zeocin resistance genes are under the control of
the IRESEMCV. We digested the Blue-script plasmid (PKs)
(Stratagene, La jolla, CA, USA) with Xho1 and EcoRV to
insert the cDNA encoding IRESEMCV (636 bp), obtained
from PCR amplification of pIRES-EGFP (Clontech, Palo
Alto, CA, USA), and obtained a PKs IRESEMCV vector. This
vector was digested by Nco1 and EcoR1 and ligated with
the cDNA encoding either CD70 or CD80, obtained from
the PCR amplification of DFG-CD70 or DFG-CD80
respectively. The PKs IRESEMCV CD70 or PKs IRESEMCV
CD80 vectors were digested by BamH1. These inserts have
been cloned into either DFG CD80 NEO or ZEO by partial
digestion using BamH1, generating the (T) tricistronic
vectors TFGEMCVNEO or TFGEMCVZEO with CD80 as first
cistron and CD70 as third cistron or in DFG CD70 NEO
or ZEO generating the same type of tricistronic vectors but
where CD70 is the first cistron and CD80 is the third
cistron.
Construction of TGFFGF-2ZEO, TGFHTLV-1ZEO, TGFC-MYCZEO or NEO
Through PCR amplification, we cloned the DNA encoding
the IRES of the human basic Fibroblast Growth factor
(FGF-2) (547 bp), the IRES of the c-myc  oncogene
(cMYC)(602 bp) and the IRES of the HTLV-1 lentivirus
(249 bp) upstream from the cDNA encoding the G418 or
zeocin resistance genes in the PKs plasmid. We generated
different combinations of cDNAs with BamH1 sites on
both the 5' and 3' ends: IRESHTLV-1-NEO, IRESHTLV-1-ZEO,
IRESFGF-2-NEO, IRESFGF-2-ZEO, IREScMYC-NEO and IRESc-
MYC-ZEO. These constructs were inserted downstream
from the gene encoding the first co-stimulatory molecule
on the BamH1 site. We generated the TFGFGF-2NEO or
ZEO, or TFGc-MYCNEO or ZEO and TFGHTLV-1NEO or ZEO
tricistronic vectors (Figure 1A). All the vectors were
sequenced.
Transfection and transduction
CRIP packaging cells were transfected with the different
plasmids using the lipofectamine technique followed or
not by selection with G418 (1 mg/ml) (from Life Technol-
ogies, GIBCO-BRL, France) or Zeocin (0.2 mg/ml)
(CAYLA, France). The resistant CRIP clones were
expanded and screened for viral titers which were of
approximately 104 viral particles/ml/48 hours/106 CRIP
cells. 293T cells were triple-transfected with the different
plasmids: TFG, pMDgag/pol and pBA-GALV. Estimation
of the viral titer in transiently transfected 293T cells
showed the presence of 106 viral particles/ml/48 hours/
106 293T cells. Fibroblasts or tumor cells (B16.F10, TS/A
or human melanoma) were transduced with the retroviral
vectors using polybrene (8 µg/ml) (SIGMA, France). The
stably transduced cells were selected using G418 or Zeocin
depending on the viral particles used, and the resistant
cells were either cloned or pooled and used in subsequent
experiments.BMC Biotechnology 2004, 4:16 http://www.biomedcentral.com/1472-6750/4/16
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RT-PCR
Cells were cultured in T-75 cm2 culture-flasks for 72 h
until they reached sub-confluence. Total RNA was isolated
from a suspension, as described by Choczynski and Sacchi
(1987) [37], of 5 × 106 cells using TRIZOL™ reagent fol-
lowing the manufacturer's recommendations (Life Tech-
nologies, Cergy Pontoise, F). RNA solutions were treated
with 5 units of DNAse 1 (Roche Diagnostics, Mannheim,
D) to remove any contaminating genomic DNA. mRNA
was transcribed into cDNA using the Ready-to-go™ kit
(Amersham Pharmacia Biotech. Inc. Piscataway, NJ, USA)
and random primers were purchased from Life Technolo-
gies. Amplification of cDNA was carried out using 1U/100
µl of Taq DNA polymerase (Roche Diagnostics, Man-
nheim, D) in a PTC-100™ Programmable Thermal Con-
troller (MJ Research, Watertown, Mass, USA) after 33
temperature cycles consisting of denaturation at 94°C (60
s), annealing at 65°C (60 s) and elongation at 72°C (120
s). The following primers were used: MFG sense primer
(Trigen 1): 5'-TGTAAAACGACGGCCAGTCACGTGAAG-
GCTGCCGACC-3', ZEO anti-sense primer (trigen 5): 5'-
CAGGAAACAGCTATGACCCACCGGAACGGCACT-
GGTC-3', ZEO sense primer (trigen 4): 5'-TGTAAAAC-
GACGGCCAGTGACCAGTGCCGTTCCGGTG-3' and
MFG anti-sense primer (trigen 10): 5'-
CAGGAAACAGCTATGACCGCCTGGACCACTGATATC-
CTGTC-3'. PCR products and the lambda/hindIII molecu-
lar weight marker (Promega, Lyon, F) were separated by
electrophoresis on 0,8% agarose (Roche, Mannheim, D),
Tris Borate EDTA (Interchim, Monluçon, F) gels and visu-
alized by staining with ethidium bromide.
Immunostaining and flow cytometric analysis
Transduced cells were stained for membrane expression of
the two co-stimulatory molecules using PE-conjugated
mouse anti-human CD70 mAb and FITC-conjugated
mouse anti-human CD80 mAb (Pharmingen, Hamburg,
D) as previously described [7]. Stained cells were analyzed
using a FACScalibur (Becton Dickinson, Mountain View,
USA).
Establishment of murine tumor models
Female C57BL/6 (H-2b), or BALB/c (H-2d) mice were
obtained from CERJ Janvier (St Quentin-Fallavier,
France). All ear-tagged mice were kept in the special path-
ogen-free animal facility in our institution and were used
for experiments between the age of 6 to 8 weeks. To estab-
lish subcutaneous (s.c.) tumors, 105 cells (twice the min-
imal tumorigenic dose) were suspended in 0.1 ml of PBS
and injected s.c. into the flank. Animals were examined
daily until the tumor became palpable, the diameter of
the tumor, in two dimensions, was then measured twice a
week. The animals were sacrificed when the tumor size
reached 2.5 × 2.5 cm in the control group. The statistical
significance of the data was established using the two
sample student's t-test. A p-value of less than 0.01 was
considered to be statistically significant.
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